Botanix Pharmaceuticals Limited
BOT
Rank in Stocks
#28095
Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the... Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections. Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis. Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.
Share Price
$0.00622971
Last synced: 2026-11-10
Market Cap
$12.41M
Change (1 day)
-10.00%
Change (1 year)
-92.36%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Botanix Pharmaceuticals Limited (BOT)
Category
Healthcare
Operating Margin for Botanix Pharmaceuticals Limited (BOT)
Operating Margin as of November 2026 TTM: -200.82%
According to Botanix Pharmaceuticals Limited's latest financial reports, its current operating margin (TTM) is -200.82%. At the end of 2025 the company had an operating margin of -1,395.62%.
Operating Margin history for Botanix Pharmaceuticals Limited from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -200.82% | -85.61% |
| 2025 | -1,395.62% | -46.61% |
| 2024 | -2,614.12% | 86.92% |
| 2023 | -1,398.49% | 141.69% |
| 2022 | -578.62% | 288.13% |
| 2021 | -149.08% | -61.73% |
| 2020 | -389.50% | -16.45% |
| 2019 | -466.18% | -62.57% |
| 2018 | -1,245.33% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | -100.00% |
| 2004 | -213.11% | 31.56% |
| 2003 | -161.99% | -4.26% |
| 2002 | -169.20% | 0.00% |
| 2001 | 0.00% | 0.00% |
| 2000 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.19% |
US
|
|
| -149.01% | -99.26% |
US
|
|
| 25.57% | -100.13% |
AU
|
|
| 31.23% | -100.16% |
BE
|
|
| 29.35% | -100.15% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Botanix Pharmaceuticals Limited's operating margin
What is Botanix Pharmaceuticals Limited's operating margin?
Botanix Pharmaceuticals Limited's operating margin is -200.82%, as of Nov 2026.
What was Botanix Pharmaceuticals Limited's operating margin in 2025?
In 2025, Botanix Pharmaceuticals Limited's operating margin was -1,395.62%, compared with -2,614.12% in 2024.
How has Botanix Pharmaceuticals Limited's operating margin changed since 2020?
From 2020 to 2025, Botanix Pharmaceuticals Limited's operating margin was highest in 2021 (-149.08%) and lowest in 2024 (-2,614.12%).
How does Botanix Pharmaceuticals Limited's operating margin compare with similar companies?
Botanix Pharmaceuticals Limited's operating margin (-200.82%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.